Research and development of innovative medicines to promote mental health are a priority for America’s biopharmaceutical research companies. With more than 130 medicines in development for mental illness, biopharmaceutical scientists are making discoveries in the lab that put treatments in the hands of patients.
Now, more than ever, we understand that the appropriate treatment of mental health conditions, once they are first recognized, can change the trajectory of an individual’s life for the better. Here at PhRMA, we are committed to the innovation that brings the next breakthrough possible and puts over 40 million patients who suffer from mental illness on the right track.
To dig deeper on mental health, PhRMA is continuing our national dialogue series with “New Cures, New Innovators for a New Era in Mental Health” today, April 18, in partnership with Axios. This event will convene leading voices to explore the current state of mental health, the science that has revolutionized treatment options and the roles that the biopharmaceutical industry, advocacy organizations and technology play to make possible these new medicines.
The program will be streamed live from 3:00 - 4:30 pm CT/4:00 - 5:30 ET, and those interested can join the conversation on Twitter with @PhRMA and #GoBoldy.
To learn more about the positive impact of the work being done by America’s biopharmaceutical companies, visit www.innovation.org.
Bill Chin, M.D. Dr. Bill Chin is the chief medical officer of PhRMA and leads the Scientific & Regulatory Advocacy department as executive vice president. A physician, an endocrinologist and an academic at heart, Dr. Chin envisions establishing PhRMA as the premiere convener in advancing drug discovery and development, regulatory sciences and collaborative partnerships.